Ticker Symbol: LRMR
Larimar Therapeutics Inc
$10.35 - 17-09-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001374690
Company Profile
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for FA. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: Three Bala Plaza East. Suite 506
Website: larimartx.com
CEO: N/A
Tags:
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Commercial Services
- Miscellaneous Commercial Services
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $3.55
Change:
-$0.22
(
-5.83%)
Days Range: $3.44 - $3.72
Beta: 0.52
52wk. High: $6.85
52wk. Low: $2.58
Ytd. Change -14.42%
50 Day Moving Average: $3.74
200 Day Moving Average: $3.86
Shares Outstanding: 43277500
Valuation
Market Cap: 15.4B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A